The recurrence of hepatocellular carcinoma (HCC) can mainly be divided into two phases or types: the intrahepatic recurrence (IHR) and the extrahepatic recurrence (EHR). Generally speaking, the EHR is usually referenced as being the less common of the two types or categories. In a post-hemihepatectomy patient with routine surveillance at 6 months, it was noted that the patient appeared to have an elevated alpha-fetoprotein, and also complained of vague lower abdominal pain. The accompanying computed tomography scan revealed a 6 cm-sized heterogeneous mass located at the pelvis region. Next, during a laparotomy for resection, the tumor was found to be bleeding from the omental deposition. In conclusion, a high index of suspicion and early surgical intervention can help in detecting possible bleeding extrahepatic recurrence in the background of a patient with history of HCC. 
INTRODUCTION

DISCUSSION
In patients with HCC, it is noted that bleeding or presence of ruptured HCC is not a common occurrence. A single center in Hong Kong documented a 9% incidence of bleeding HCC from the total number of cases of HCC seen over a 10 year period. 3 The diagnosis may be difficult, as this condition may mimic other forms of intraabdominal pathologies, and requires a high index of suspicion. As of now there are no standard algorithms of related treatment approaches to be utilized in dealing with recurrent HCC. The definitive management usually ranges from conservative, the use of minimally invasive approaches via endovascular embolization to surgery with plication, hepatic artery ligation, alcohol injection, double stage procedure (packing then definitive) or definitive procedure in a single setting. 4 In these cases, the 30-day mortality was measured to be 38%. 3 The pattern of extrahepatic recurrence can then further be grouped into 3 patterns. Pattern I represented patients whose first recurrence was noted in the liver and in whom an extrahepatic metastasis developed later after repetitive locoregional treatments; pattern II included patients in whom both intrahepatic and extrahepatic recurrences were evident when recurrence was identified; and pattern III included patients who had only extrahepatic metastasis without intrahepatic metastases at the time of diagnosis of metastasis. Out of these groups, it is noted that the group 3 is considered the rarest group. 5 The incidence of bleeding in a metastatic HCC is uncommon. Not many recent case reports are available discussing the incidence of a ruptured bleeding metastatic/recurrent HCC. One case shows a post mortem report of a ruptured peri-pancreatic lymph node; along with a histopathological examination of which returned as conclusively reported metastatic HCC. 6 Another article discussed two patients being treated with HCC who were originally presenting with an acute abdomen. 7 In these cases, with the CT imaging showing peritoneal tumor seeding and hematoma, the patients were operated to achieve hemostasis. The nodules which were sent for histopathological examination also confirmed the presence of a metastatic HCC. 7 These bring us to understand that the route of extrahepatic HCC spread has been postulated from travel through tumor cells via lymphatics, vessels, direct extension or seedling. 8 In this case report, the possibility of existing tumor deposit during the first operation cannot be ruled out, although the serum AFP did show a drastic drop post-surgery.
In conclusion, a bleeding metastatic HCC can be equally difficult to diagnose and as difficult to treat. A high index of suspicion is required in these cases, and an intervention should be recommended after a full review as on a timely basis. There are no protocols for this type of treatment, therefore treatment should be tailored to each patient and patient situation.
